• News

    SeekIn (Shenzhen, China) has developed several blood-based solutions to simplify and enhance cancer diagnosis and analysis. This technology can be easily adopted in many countries for early detection, treatment response and recurrence monitoring. All for the benefit of patients who will have...
    SeekIn said on Wednesday that it has received CE marking for its SeekInClarity Cancer Treatment Response Monitoring Kit. https://www.genomeweb.com/molecular-diagnostics/seekin-gets-ce-mark-cancer-treatment-response-monitoring-kit  
    SeekIn said on Thursday that it has received CE marking for its LeukoPrint Molecular Karyotyping Kit for the diagnosis and stratification of leukemia patients. https://www.genomeweb.com/molecular-diagnostics/seekin-gets-ce-mark-leukemia-molecular-karyotyping-kit  
    SHENZHEN, China, Feb. 24, 2022 /PRNewswire/ -- SeekIn Inc, the leader in blood-based cancer early detection and monitoring technology, today announced the CE (Conformité Européenne) Mark for SeekInCare® Cancer Detection Kit and is now ready to launch this test in European markets. https://www...
    SHENZHEN, China – August 16th, 2021 – SeekIn Inc. (hereinafter referred to as “SeekIn”) today announced that it has obtained a license from Bio-Rad Laboratories, Inc., to develop and market oncology precision medicine molecular diagnostic test kits utilizing Bio-Rad’s Droplet Digital® PCR (ddPCR®...

    ©2018 SeekIn Cancer. All Rights Reserved.